PremiumThe FlyXBiotech trading resumes XBiotech announces data from Phase 1/2 1-BETTER study XBiotech trading halted, volatility trading pause PremiumThe FlyXBiotech treats first patient in Phase II RA trial of Natrunix XBiotech announces first subject enrollment in Phase I trial for Hutrukin